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Abstract (290 words max 300) 
Background: Even with newly approved treatments, metastatic melanoma remains a life-
threatening condition. We conducted a worldwide multicentre Phase 3 trial to evaluate the 
efficacy of the MAGE-A3 immunotherapeutic in patients with Stage IIIB or IIIC melanoma in 
the adjuvant setting.  
Methods: DERMA was a randomised, double-blind, placebo-controlled trial in patients aged 
at least 18 years with MAGE-A3-positive histologically proven, completely resected Stage 
IIIB or IIIC cutaneous melanoma with macroscopic lymph node involvement. Patients were 
to have a performance score of 2 or less. Patients were randomly assigned (2:1) to receive 
up to 13 intramuscular injections of recombinant MAGE-A3 with AS15 immunostimulant 
(MAGE-A3 immunotherapeutic) or placebo over a 27-month period: 5 doses at 3-weekly 
intervals, followed by 8 doses at 12-weekly intervals. Randomisation and treatment 
allocation at the investigator site was done centrally via internet with stratiﬁcation for the 
presence of a predictive gene signature versus no gene signature. Participants, 
investigators, and those assessing outcomes were masked to group assignment. A 
minimisation algorithm accounted for disease stage, nodal stage, stage of the primary 
tumour, extra-capsular extension of the lymph node, study centre and prior treatment with 
interferon and/or anti-CTLA4 drugs. The co-primary objectives were: efficacy in terms of 
disease-free survival (DFS) in the overall population, and DFS in patients with a potentially 
predictive gene signature (GS+) identified previously. The gene signature was defined and 
prospectively validated using an adaptive signature design. The ﬁnal analyses included the 
total treated population (all patients who had received at least one treatment dose). This trial 
is registered with ClinicalTrials.gov, number NCT00796445. 
Findings: Of 3,914 patients screened, 2,092 had a MAGE-A3-positive tumour, 1345 were 
randomized and started treatment. At the final analysis (median follow-up 28·0 months 
[interquartile range, IQR, 23·3-35·5] in the MAGE-A3 group and 28·1 months (IQR 23·7-
36·9) in the placebo group), median DFS was 11·0 months (95% CI 10·0-11·9) in the 
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MAGE-A3 group and 11·2 months (95% CI 8·6-14·1) in the Placebo group (Hazard Ratio 
[HR] 1·01, 95% CI 0·88-1·17, p=0·86). Median DFS in the GS+ population was 9·9 (95% CI 
5·7-17·6) and 11·6 months (95% CI 5·6-22·3) in the respective treatment groups (HR 1·11, 
95%CI 0·83-1·49, p=0·48). Within 31 days of treatment, adverse events (AEs) grade 3 
were reported by 14% of patients in the MAGE-A3 group and 12% in the Placebo group; 
treatment-related AEs grade 3 by 4% versus 1%, respectively; and 1 serious AEs by 14% 
of patients in both groups. The most frequently reported grade 3 or higher adverse events 
were neoplasms (33 [4%] in the MAGE-A3 group and 17 [4%] in the Placebo group), general 
disorders and administration site conditions (25 [3%] versus 4 [<1%]) and infections and 
infestations (17 [2%) versus 7 [2%]). There were no treatment-related deaths. 
Interpretation: An antigen specific immunotherapeutic alone was not efficacious in this 
clinical setting. Based on these results, development of the MAGE-A3 immunotherapeutic for 
use in melanoma has been stopped.  
Funding: GlaxoSmithKline Biologicals SA 
 
 
 
This is the last approved revised version prior to journal acceptance. This version differs from the final 
version following Editorial change prior to publication. 
7 
Introduction (4483, max 4500 words) 
Melanoma is the most aggressive form of skin cancer and 5-year overall survival (OS) in 
patients with stage IIIB/IIIC disease is 35%-60%.1 Treatment is complete surgical resection, 
but patients with stage IIIB disease (macroscopic involvement of lymph nodes [LN]) remain 
at high risk of relapse, that increases with the number of invaded LN and capsular extension.  
Adjuvant therapies such as interferon-alpha and pegylated interferon prolong relapse-free 
survival but do not appear to influence OS significantly, with discordant clinical results 
according to the dose, duration and targeted population.2,3 Adjuvant ipilimumab has been 
shown to improve relapse-free survival and OS, but more than half of patients experience 
grade III-IV toxicity, and some die.4 Two recent studies have shifted the landscape in 
adjuvant melanoma treatment. First, Nivolumab as adjuvant treatment among patients with 
resected stage IIIB, IIIC and IV melanoma resulted in significantly longer recurrence-free 
survival with lower rates of severe toxicity compared to Ipilimumab.5 Second, the 
combination of the BRAF inhibitor dabrafenib plus the MEK inhibitor trametinib significantly 
lowered the risk of recurrence in patients with stage III melanoma with BRAF V600E or 
V600K mutation when compared to placebo.6 The safety profile of dabrafenib plus trametinib 
was consistent with that observed with this combination in patients with metastatic disease. 
The MAGE-A3 cancer-testis tumour antigen is expressed in up to 76% of melanomas, but 
the gene is silent in all normal human tissues except placenta and testis.7,8 The MAGE-A3 
immunotherapeutic (GSK) comprises a recombinant MAGE-A3 protein (recMAGE-A3) 
administered with the GSK proprietary immunostimulant AS15, and was designed to 
enhance both humoral and cell-mediated responses against MAGE-A3-expressing tumours.9 
In a Phase 2 proof-of-concept study in patients with early progressive metastatic melanoma, 
an objective clinical response was observed in 5/72 patients treated, and another 10 patients 
showed disease stabilisation.10 The Phase 2 study evaluated recMAGE-A3 combined with 
two different immunostimulants, AS02B or AS15. Both immunostimulants had a similar safety 
profile, and four of the five objective responses were in the 37 patients who received AS15. 
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Based on these results and those of previous preclinical and clinical studies,11-13 AS15 was 
selected for further development. These results, along with encouraging results in a 
randomized Phase 2 study of the MAGE-A3 immunotherapeutic in patients with non-small-
cell lung cancer (NSCLC),14 were considered sufficient to commence a worldwide, 
multicentre, Phase III study to evaluate the clinical efficacy of the MAGE-A3 
immunotherapeutic in patients with stage III melanoma with macroscopic LN involvement.  
An immune-related gene signature associated with clinical benefit following immunisation 
with the MAGE-A3 immunotherapeutic was identified in the Phase 2 proof-of-concept 
melanoma study, and retrospectively validated in the Phase 2 NSCLC study.10,14,15 
Therefore, the DERMA study also sought to optimise and prospectively validate this 
candidate predictive gene signature using an adaptive signature design.16,17   
Methods 
Study design and participants 
In this double-blind, randomised, placebo-controlled Phase 3 study conducted in 31 
countries, we recruited patients aged 18 years who had histologically proven, completely 
resected  stage IIIB or IIIC cutaneous melanoma with macroscopic LN involvement defined 
according to the TNM staging system (sixth edition).  A summary of the protocol is located at 
https://www.gsk-clinicalstudyregister.com/search/?study_ids=111482. 
Eligible patients had to have been surgically rendered disease-free no more than 9 weeks 
before randomisation. Patients with unknown primaries were also eligible (TxN1b-N2b-N3 
M0). For patients undergoing elective regional LN dissection followed by lymphadenectomy, 
the date of the radical lymphadenectomy was considered the day the patient was disease-
free. Quantitative MAGE-A3 gene expression was determined by reverse transcriptase-
polymerase chain reaction (RT-PCR) analysis on formalin-fixed paraffin-embedded tissue. At 
the time of randomisation, patients had to have adequate renal and hepatic function and 
bone-marrow reserve, and an Eastern Cooperative Oncology Group performance score <2.   
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All patients gave written informed consent for MAGE-A3 expression screening and gene 
expression profiling, and for study participation. Prior systemic treatment with an 
immunomodulator (i.e., interferon and/or anti-CTL-A4) following a previous surgery was 
allowed, provided that a wash-out period of 30 days before randomisation was respected. 
Previous radiotherapy was allowed, provided that the treatment had been completed before 
the lymphadenectomy that qualified the patient for study participation.  
Patients were excluded if they had a history of autoimmune disease (excluding vitiligo), 
infection with Human Immunodeficiency Virus, another confirmed or suspected 
immunosuppressive or immunodeficient condition, psychiatric or addictive disorders that 
may have compromised his/her ability to give informed consent or to comply with the study 
procedures, severe concurrent severe medical problems that would limit full compliance with 
the study or expose the patient to unacceptable risk, previous or concomitant malignancies 
(except effectively treated non-melanoma skin cancers, carcinoma in situ of the cervix or 
effectively treated malignancy that had been in remission for over 5 years and was highly 
likely to have been cured), or an uncontrolled bleeding disorder. Amendments to the 
protocol, exclusion criteria, efficacy and safety follow-up procedures and patient withdrawal 
information are provided in appendix (p13-15).  
This study was conducted in accordance with the principles of "good clinical practice", the 
principles of the Declaration of Helsinki and all applicable regulatory requirements. The 
protocol was approved by national, regional, or investigational centre institutional review 
boards or ethics committees. During the course of the study, whenever potential or actual 
issues with regard to the conduct of the study were identified, either via site monitoring 
activities or brought to GSK’s attention by other oversight mechanisms, these issues were 
investigated and whenever possible, appropriate corrective/preventive actions were taken. 
An Independent Data Monitoring Committee (IDMC) monitored the study and reviewed study 
endpoints and safety data.  
Randomisation and masking 
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Patients were randomised 2:1 to receive either the MAGE-A3 immunotherapeutic or placebo 
at the investigator site using a central internet randomisation system. The randomization and 
treatment number assignment was handled centrally at GSK Vaccines. The central 
randomization system was accessed by staff at the investigator site using internet. The 2:1 
ratio was used to make a potentially active treatment available to a larger proportion of trial 
subjects. A minimisation algorithm (with a 10% random element) accounted for disease 
stage (IIIB or IIIC or IIIx (undefined stage III Tx)), nodal stage (N1 or N2 or N3), stage of the 
primary tumour (Tx-0 or T1-2 or T3 or T4), extra-capsular extension of the LN (yes or no), 
study centre and prior treatment with interferon and/or anti-CTLA4 (cytotoxic T-lymphocyte-
associated antigen 4) drugs (yes or no). 
Individual treatment assignment was masked at all levels except to the IDMC and the 
independent statistician performing 6-monthly safety assessments and efficacy analyses. 
The study remained blinded until the primary analysis of disease-free survival (DFS) in the 
GS+ population (patients with a gene signature potentially predictive of a treatment benefit), 
which occurred 2 years after the primary analysis of DFS in the overall population due to the 
development and analytical validation of the gene expression assay. 
Procedures  
The composition and treatment schedule of the MAGE-A3 immunotherapeutic and placebo 
are provided in appendix (p6). Patients were to receive up to 13 intramuscular injections of 
MAGE-A3 immunotherapeutic or placebo over a 27-month period: 5 doses at 3-weekly 
intervals, followed by 8 doses at 12-weekly intervals. No dose reductions were permitted, but 
doses could be skipped or delayed if the patient was acutely ill at the time of the scheduled 
administration, if influenza vaccine or blood products needed to be given (with at least a 7-
day interval between vaccination/blood products and treatment), any other medical reason 
considered by the investigator that would expose the patient to an unacceptable risk. In case 
of postponement of study treatment administration for any reason, a visit to administer the 
missed treatment had to be planned as soon as possible to catch up the originally planned 
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schedule. The next study visit had to be planned at a time allowing a minimum of 14 days 
between two treatment administrations and to keep up with the schedule as based on the 
date of first study treatment administration.  
Patients were required to discontinue treatment if any of the following criteria became 
applicable: evidence of disease recurrence; receipt other anti-cancer treatments or 
investigational products; any grade 3 or more allergic reaction following the administration of 
study treatment; any intolerable AE or persistence moderate AE that could be worsened by 
further administration of study treatment; signs or symptoms of an immune disorder (except 
vitiligo); any immune deficient/suppressive condition, inability of the patient to complete the 
study evaluations, development of other conditions for which, according to the investigator, it 
was in the patients best interests to withdraw, patient request, and for female patients, 
pregnancy or the decision to become pregnant.    
Procedures for the assessment of eﬃcacy are provided in appendix (p16). Eﬃcacy 
assessments during treatment were done every 3 months, alternating chest and upper 
abdomen CT-scans or chest x-rays. At every visit, the investigator performed a physical 
examination and clinical assessment. Brain CT or MRI were done if clinically indicated. 
Active follow-up for survival and disease recurrence was planned to continue for at least 5 
years from the first study treatment.  
Due to multiple differences in assays, sample type and clinical setting between the Phase 2 
and Phase 3 studies, optimisation and clinical validation of the gene signature were done 
using a split-sample approach based on the adaptive signature design.16,17 In summary, the 
first set of patients (‘training set’, one-third of study patients) was used to define a predictive 
gene signature that could identify patients most likely to benefit from treatment, different 
gene signature classification models were evaluated in the training set, starting with 55 
target genes measured by quantitative real-time PCR (qRT-PCR). The remaining two-thirds 
of patients comprised the ‘test set’ that was used for clinical validation of the selected gene 
signature after the final analysis of the first co-primary endpoint and validation of the gene 
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signature assay. Details of the qRT-PCR assay, steps and methods for classifier 
development and clinical validation of a multigene predictive gene signature are provided in 
appendix (from p39).  
The schedule for laboratory evaluations of safety and reporting period for adverse events 
(AEs) is provided in appendix (p15). The investigator inquired about the occurrence of AEs, 
SAEs, pregnancy and autoimmune diseases at every visit/contact during the study and 
throughout the follow-up period. Patients were instructed to contact the investigator 
immediately in case of signs or symptoms they perceived as serious. AEs were recorded for 
31 days (day 0-30) after each dose. Serious adverse events (SAEs) were recorded from 
study start until the end of the treatment phase. SAEs related to the investigational drug or 
any concurrent GSK drug were recorded from consent until study end. New onset of 
autoimmune disease and pregnancies were recorded from the first treatment for 5 years. AE 
intensity was graded by the investigators using Common Terminology Criteria for Adverse 
Events (CTCAE Version 3.0).18 Individual AEs were coded to the Preferred Term level using 
the Medical Dictionary for Regulatory Activities (MedDRA). The investigator assessed 
potential causal relationships between the investigational product and each AE.  
Safety laboratory assays assessing the haematological parameters, renal and hepatic 
functions were performed during screening, and at week 12, month 12, month 24 and month 
30. Additional tests could be performed if clinically indicated. Using an enzyme-linked 
immunosorbent assay performed centrally at GSK’s laboratories,19 we measured anti-
MAGE-A3-specific immunoglobulin-G antibodies at baseline, after 2, 4, 6, 7, 9 and 13 
treatment administrations and one year post-treatment conclusion. Seropositivity was 
defined as an antibody titre assay cut-off of 27 EU/ml.  
Health-related quality-of-life (QoL) utility was assessed using the EuroQoL-5D (EQ-5D) 
questionnaire.20 Patients self-completed the questionnaire prior to injection at treatment dose 
1, 3, 5, 6, 7, 8, 12, at the first follow-up visit, and again after the patient had been informed of 
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a recurrence before starting a new anti-cancer treatment. QoL was re-assessed by staff via 
telephone on the day after injection on visits 1, 3 and 5.  
Outcomes 
The co-primary study objectives were to demonstrate clinical efficacy of the MAGE-A3 
immunotherapeutic compared to placebo in terms of disease-free survival (DFS, defined as 
the interval from randomisation to either the date of first disease recurrence or death due to 
any cause) in the overall population (objective 1), and in the population presenting a 
potentially favourable predictive gene signature (objective 2). Secondary endpoints were OS 
(the interval from randomisation to the date of death due to any cause), DFS at 2, 3, 4 and 5 
years, disease-free specific survival (DFSS: the interval from randomisation to the date of 
first recurrence or death due to melanoma) and distant metastasis-free survival (DMFS: the 
interval from randomisation to the date of first distant metastasis or date of death (any 
cause)). Other secondary outcomes were immunogenicity (MAGE-A3 seropositivity rates); 
the occurrence of AEs up to 30 days after each study dose, and of SAEs and autoimmunity 
up to 30 days after the last administration of study treatment; and the EQ-5D Utility Score 
and Visual Analog Score and change from baseline. All endpoints were calculated in the 
overall population, and in the populations with and without a favourable gene signature (GS-
/GS+).  
Statistical analysis 
In order to control the two-sided type I error <5%, a Bonferroni adjustment was applied with 
a 2-sided 4·00% alpha assigned to objective 1 and a 2-sided 1·00% alpha assigned to 
objective 2. To detect a relevant increase in median DFS in the overall population with a 2-
sided nominal alpha of 4·00% and a power of 80%, the study needed to randomise 1300 
patients to reach 850 events at time of final analysis. This number of events was based on 
simulations taking into account a potential delayed treatment effect, assuming a HRof 0·90 
during the first 2 months following randomisation and HR of 0·77 subsequently. The second 
objective was to be assessed on the test set of two-thirds of patients with a sample 
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available. Assuming that 50% of patients were GS+, at least 184 events were anticipated to 
be observed in patients allocated to the test set at the final analysis; which would provide 
80% power to detect a statistically significant treatment difference in DFS at the two-sided 
1·00% significance level, assuming a HR of 0·59.  
The primary analysis of efficacy on the Total Treated cohort included all randomised patients 
who had received at least one treatment dose, using the treatment assignment as 
randomised. Hazard ratios (HR) were estimated using a Cox proportional hazards 
regression using randomisation-minimisation factors (except study centre) and ulceration 
status as covariates in the model.21 The efficacy analyses in the population of test set 
patients presenting with the potentially favourable predictive gene signature were also 
adjusted for the prognostic gene signature score (a gene signature associated with a worse 
clinical prognosis in the placebo arm) (appendix p13), prospectively defined in the training 
set as the 8-gene-Th1/IFNƴ gene expression signature.22  Additional details are provided in 
Appendix (p17). Safety analyses were conducted on the Total Treated cohort that included 
all randomised patients who had received at least one treatment dose, according to the 
actual treatment received.  
The analysis of immunogenicity was performed on the according-to-protocol immunogenicity 
cohort that included all eligible patients who complied with protocol-defined procedures, who 
had received at least first four consecutive treatment doses and for whom immunogenicity 
data were available. The final analysis of DFS in the overall population (first co-primary 
objective) was performed when at least 850 events had occurred in the overall population 
(database cut-off date 23 May 2013). The final analysis of DFS in the GS+ population 
(second co-primary objective) was done in August 2015 and was performed on the same 
clinical database after technical development and validation of the gene expression assay.  
In the primary analysis of efficacy, groups were compared using the Likelihood Ratio test. 
Non-parametric estimates of median time-to-event endpoints were generated using Kaplan-
Meier methodology with confidence intervals (CI) calculated using the Brookmeyer and 
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Crowley method. All CI were 95% two-sided nominal, and all reported p-values were two-
sided. The co-variates for efficacy analyses were based on values recorded in the patient 
case report form, except when missing, in which case the value reported at randomization 
was used. An exploratory predictive factor analysis was also performed using a likelihood 
ratio test for interaction between the baseline covariate and treatment after including both as 
main effects in a Cox model. Only patients with all baseline values available were 
considered in the predictive analysis. A few patients with an ineligible stage were pooled with 
the closest category. Results for categorical variables were presented in forest plots. 
Sensitivity analyses of the co-primary endpoints used different analysis methods or models. 
DFS was analysed using a Logrank test without stratification, and stratified by the 
minimization factors (except centre) and ulceration status. For these analyses, estimates of 
the HR and 95% CI were obtained by an unadjusted Cox model. An analysis of DFS used a 
Cox model adjusted for all baseline covariates. The likelihood ratio test was used to compare 
the groups. Sensitivity analyses were also conducted using variations of the DFS endpoint 
definition: taking the date of previous assessment date as date of event for patients with a 
recurrence, considering the start of a new therapy for a melanoma recurrence before a 
documented recurrence as an event, and using the GSK assessment of the recurrence date. 
EuroQoL-5D (EQ-5D) health dimensions, utility values and Visual Analogue Scores and their 
changes from baseline were reported descriptively. Differences between the two treatment 
groups were compared per time point using the non-parametric Wilcoxon test. No correction 
for multiple testing was applied. An exploratory analysis assessed changes in mean scores 
over time and overall with a repeated measures analysis using a mixed effects model. 
Statistical analyses were performed using SAS (version 9.2). This study is registered with 
www.clinicaltrials.gov, number NCT00796445. 
Role of the funding source 
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The study was designed and interpreted by GlaxoSmithKline Biologicals SA in cooperation 
with an international Steering Committee. Data collection, statistical analysis and writing 
assistance were provided by GlaxoSmithKline Biologicals SA. BD, CD and MD had access 
to the raw data. All authors had access to the results and final responsibility for the analysis, 
interpretation and submission. The corresponding author had full access to all of the data 
and final responsibility for publication submission. 
 
Results 
The first patient was screened on 01 December 2008 and the last patient was randomized 
on 19 September 2011. There were 3914 patients screened at 263 centres; 3182/3914 
(81%) patients had a valid tumour sample and 2092/3182 (66%) of these had a MAGE-A3-
positive tumour (Figure 1). There were 1345 patients who were randomised and received at 
least one dose of treatment and contributed to the final analysis. Between the final and 
follow-up analyses, one patient was found to have an invalid consent form and was not 
included in the follow-up analysis (N=1344).  
The study groups were comparable in terms of baseline characteristics (Table 1). Overall, of 
1345 patients 724 (54%) patients had Stage IIIC disease, 479 (36%) had ulceration of the 
primary tumour, 448 (33%) had extracapsular LN extension and 202 (15%) had received 
prior treatment with interferon and/or anti-CTL-A4 drugs. Median time from 
lymphadenectomy to randomization was 7·1 weeks in both groups (interquartile range [IQR] 
5·9-7·9). The percentage of patients with an unknown primary was 18·1% in the MAGE-A3 
group and 16·8% in the placebo group.  
There were 786/895 (88%) patients in the MAGE-A3 group and 403/450 (90%), in the 
Placebo group who received at least four treatment doses. The number of patients who 
received all 13 doses was 256/894 (29%) in the MAGE-A3 group and 133/450 (30%) in the 
Placebo group.  
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Reasons for treatment or study withdrawal were distributed similarly in each group (Figure 
1). There were 4 patients (all in the MAGE-A3 group) who discontinued treatment due to an 
AE considered by the investigator to be related to vaccination; rash, autoimmune hepatitis, 
fatigue and influenza-like-illness. There were 3 patients (all in the MAGE-A3 group) who 
discontinued treatment due to an SAE considered by the investigator to be related to 
vaccination; polyneuropathy, pyrexia and blurred vision.  
All 1345 patients in the Total Treated population were included in the analysis of efficacy in 
the overall population. The median duration of follow-up at the time of the final analysis was 
28·0 months (IQR 23·3-35·5) in the MAGE-A3 group and 28·1 months (IQR 23·7-36·9) in 
the Placebo group (p=0·44). 
At the time of the final analysis there were 856 events (recurrence or death): 572 events in 
893 patients (64%) in the MAGE-A3 group and 284/452 (63%) in the Placebo group. 
Disease recurred in 565/893 (63%) of patients in the MAGE-A3 group and in 283/452 (63%) 
in the Placebo group. The additional DFS events were 8 deaths in absence of recurrence (7 
in the MAGE-A3 group, 1 in the Placebo group).  
Overall median DFS at the time of the final analysis was 11·0 months (95% CI 10·0-11·9) in 
the MAGE-A3 group and 11·2 months (95% CI 8·6-14·1) in the Placebo group (HR 1·01, 
95% CI 0·88-1·17, p=0·86) (Figure 2). Exploratory subgroup analyses according to baseline 
demographics, tumour and treatment parameters showed that the estimated HRs CI 
included ‘1’ for all parameters, except for nodal stage (Figure 3).  
There were 366 patients allocated to the training set and 729 to the test set. Of the training 
set samples, 357 gave valid qRT-PCR results. The gene signature discovered in the Phase 
2 studies, summarised by eight of the pre-selected genes (Th1/IFNƴ gene signature) was 
identified as being associated with clinical outcome in the placebo arm of the training set 
(prognostic effect) 22 independent from all other pre-defined clinical prognostic factors, and 
was used as a covariate to adjust the final statistical analysis. Adjusting for the prognostic 
effect of this signature in the training set, a clinical benefit of MAGE-A3 immunotherapeutic 
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over placebo was observed in DFS for patients selected (GS+) with a novel potentially 
predictive gene signature classifier set up in the training set (appendix p44-45). As per the 
study protocol, the study team remained blinded to the result in the overall population. When 
this new predictive gene signature was applied to the remaining two thirds of the samples 
(test set), the median DFS in the GS+ population was 9·9 months (95% CI 5·7-17·6) in the 
MAGE-A3 group and 11·6 months (95% CI 5·6-22·3) in the Placebo group (HR 1·11, 95% CI 
0·83-1·49, p= 0·48) (Figure 2). The number of DFS events in the test set GS+ population 
was 124/200 (62%) in the MAGE-A3 group and 72/116 (62%) in the Placebo group. There 
was no difference between the MAGE-A3 and Placebo groups in the GS+ or GS- 
populations in terms of DFS, OS, DFSS or DMFS, or in the assessment of DFS for each 
year of follow-up (appendix p18-19). Exploratory subgroup analyses of GS+ and GS- 
populations showed that the estimated HRs CI included ‘1’ for all parameters (appendix p34-
35). 
DFS in the MAGE-A3 group and the Placebo group was 46·6% (95% CI 43·2-49·8) and 
46·7% (95% CI 42·0-51·2), respectively at year 1, 37·2% (95% CI 34·0-40·4) and 38·8% 
(95% CI 34·2-43·3) at year 2, 33·2% (95% CI 29·7-36·6) and 34·9% (95% CI 30·1-39·8) at 
year 3 and 30·7% (95% CI 26·7-34·7) and 32·5% (95% CI 26·9-38·2) at year 4.  
Overall, 467 patients died, 314/893 (35%) in the MAGE-A3 group and 153/452 (34%) in the 
Placebo group. Median OS was reached in the Placebo group (46·6 months, 95% CI 39·6-
not reached) but not in the MAGE-A3 group (HR 1·07, 95% CI 0·88-1·29, p=0·52). 
There were 850 DFSS events (566/893 [63%] in MAGE-A3 and 284/452 [63%] in Placebo) 
and 743 DMFS events (502/893 [56%] in MAGE-A3 and 241/452 [53%] in Placebo). The 
median DFSS was 11·1 months (95% CI 10·4-12·3) in the MAGE-A3 group and 11·2 (95% 
8·6-14·1) in the Placebo group (HR 1·00, 95% CI 0·87-1·16; p=0·98). The median DMFS 
was 18·7 months (95% CI 16·3-22·1) and 23·9 months (95% CI 18·9-30·7), respectively,  
(HR 1·09, 95% CI 0·94-1·27; p=0·27). 
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The results of the follow-up analysis were consistent with the final analysis (appendix p17). 
All sensitivity analyses of the primary endpoints were consistent with the main conclusion of 
absence of treatment effect. 
The final and follow-up analyses were reviewed by the IDMC. Based on their feedback and 
the lack of treatment effect for both co-primary endpoints, the study was terminated early, on 
8 September 2015. This decision was based exclusively on the efficacy endpoints 
assessment and on the fact that by stopping the study, the participating patients would not 
be exposed to unnecessary study-related procedures. At the time of the decision, 308 
patients were still on the study worldwide (follow-up phase).  
AEs within 31 days of treatment administration were reported by 92% (822/894) of MAGE-
A3 and 74% (334/450) of Placebo recipients (Table 2). The most frequently reported AEs 
were pyrexia, injection site pain and influenza-like illness, all of which were more common in 
the MAGE-A3 group. Most AEs reported within 31 days of treatment administration in each 
group were grade 1 or 2. In the MAGE-A3 group, 14% (126/894) of patients experienced 
AEs grade 3 or above, compared to 12% (56/450) in the Placebo group. The most frequently 
reported grade 3 or higher adverse events were neoplasms (33 [4%] in the MAGE-A3 group 
and 17 [4%] in the Placebo group), general disorders and administration site conditions (25 
[3%] versus 4 [<1%]) and infections and infestations (17 [2%) versus 7 [2%]). Treatment-
related grade 3 or above AEs within 31 days of treatment occurred in 4% (36/894) and 1% 
(6/450) of patients in the MAGE-A3 and Placebo groups, respectively. No related grade 4 or 
grade 5 AEs in either group was reported.  
At least one SAE was reported by 14% of patients in both groups (129/894 in the MAGE-A3 
group and 64/450 in the Placebo group) (appendix p24).  The most frequently reported SAEs 
according to MedDRA System Order Class (SOC) were ‘Neoplasm benign, malignant and 
unspecified’ (6% [55/894] in the MAGE-A3 group and 5% [24/450] in the Placebo group), 
‘Infection and Infestations’ (3% [30/894] and 3% [14/450], respectively). All other MedDRA 
SOCs were represented by 1% of patients in each group.  
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SAEs considered to be treatment related by the investigator were reported in <1% (8/894) of 
patients in the MAGE-A3 group (Pyrexia, Autoimmune thyroiditis, Polyneuropathy, 
Erysipelas, Wound infection, Vision blurred, Lymphadenitis, Subarachnoid haemorrhage) 
and <1% (4/450) in the Placebo group (Retinopathy, Thrombocytopenic purpura, Invasive 
lobular breast carcinoma, Pain in extremity). The same treatment-related SAE was not 
reported in more than one patient within the same group.  
Fatal (Grade 5) SAEs that occurred at any time from randomisation until the end of study 
were reported in <1% of patients in both study groups (5/894 patients in the MAGE-A3 group 
and 1/450 in the Placebo group (Appendix p25). None of the fatal SAEs were considered 
treatment-related as per investigator assessment.  
New onset of potential immune-mediated diseases (pIMDs) occurred in 4% (33/894) of 
patients in the MAGE-A3 group, and 5% (23/450) in the Placebo group. pIMDs were 
distributed over 11 MedDRA SOCs (Table 4). Aside from vitiligo (20 cases in the MAGE-A3 
group and 13 cases in the Placebo group), only autoimmune thyroiditis (3 cases in the 
MAGE-A3 group) and sarcoidosis (2 cases in the Placebo group) were reported by more 
than one patient per group. pIMDs considered by the investigator to be treatment-related 
were reported by 3% of patients in both groups (26/894 in the MAGE-A3 group, 12/450 in 
the Placebo group). Of these, 19 in the MAGE-A3 group and 11 in the Placebo group were 
cases of vitiligo.  
There were 14/894 (2%) patients in the MAGE-A3 group and 5/450 (1%) in the Placebo 
group who discontinued study treatment prematurely due to AEs. Of these, 7 patients in the 
MAGE-A3 and no patients in the Placebo group discontinued due to an AE assessed as 
treatment-related. 
Results for the GS+ and GS- populations mirrored those of the overall population (appendix 
p26-27). 
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One dose was skipped by 8 patients (0·9%) in the MAGE-A3, 5 patients (1·1%) in the 
Placebo group, and 2 doses were skipped by one patient (0·1%) in the MAGE-A3 group. In 
the MAGE-A3 group, five patients had reached the maximum delay for postponing the 
treatment, one patient had an AE, one had an SAE and 3 doses were skipped for other 
reasons. In the Placebo group 3 patients had reached the maximum delay for postponing the 
treatment, and two were skipped for other reasons). 
At least one dose was delayed in 181 patients (20·2%) in the MAGE-A3 group and by 93 
patients (20·7%) in the Placebo group. Reasons for delaying doses were AEs (25/370 
delayed doses, 6·8%, in the MAGE-A3 group and 10/185 delayed doses, 6·3%, in the 
Placebo group), SAEs (13/370, 3·5% and 1/185, 0·5%, respectively), other reasons 
(323/370, 87·3% and 169/185, 91·4%) and reason not known (9/370, 2·4% and 5/185, 
2·7%, respectively).  
Antibody geometric mean concentrations increased rapidly with MAGE-A3 
immunotherapeutic treatment and remained elevated throughout the treatment period 
(appendix p36). Results for the GS+ and GS- populations mirrored those of the overall 
population (appendix p37). 
Mean utility scores between 0·80 and 0·90 were observed during the treatment period. The 
mixed effect repeated measures analysis of change from baseline in EQ-5D utility scores 
over time identified a statistically significant detrimental effect of treatment on the day after 
the first, third and fifth treatment administrations, and at recurrence (day after visit 1 mean -
0·067 standard deviation [SD] 0·011 on MAGE-A3 and 0·020 [0·016] on placebo; p<0·0001); 
day after visit 3 -0·129 [0·011] on MAGE-A3 and 0·019 [0·016] on placebo; p<0·0001; day 
after visit 5 -0.060 [0·012] on MAGE-A3 and 0·022 [0·018] on placebo; p=0·0001, at 
recurrence -0·100 [0·017] on MAGE-A3 and -0·029 [0·027] on placebo; p=0·026). At year 1, 
the difference was in favour of the MAGE-A3 group (mean at year 1 of follow-up -0·067 [SD 
0·0277] on MAGE-A3 and -0·208 [0·044] on placebo; p=0·0057).  
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The same observation was made for visual analogue scores on the day after the first and 
third administrations (day after visit 1 mean -7·879 [SD 1·497] on MAGE-A3 and 0·398 
[2·203] on placebo; p=0·0019); day after visit 3 -8·820 [1·510] on MAGE-A3 and 0·328 
[2·216] on placebo; p=0·0007). There was evidence of a group difference for the change 
from baseline in the overall model for utility score (adjusted mean -0·037 [SD 0·010] for 
MAGE-A3 and 0·002 [0·011] for placebo; p=0·0006). There was no evidence of a group 
difference in the change from baseline in the visual analogue scores in the overall model 
(adjusted mean -4·025 [SD 1·283] for MAGE-A3 and -1·268 [1·532] for placebo; p=0·0683) 
(see appendix p28-32). The decreased scores on MAGE-A3 treatment after the first and 
third treatment administrations are most likely related to the dimension pain/discomfort at the 
injection site. This observation from the descriptive EQ-5D analysis is consistent with the 
clinical safety results.  
Discussion 
To our knowledge, this is the largest adjuvant trial ever conducted in melanoma. Treatment 
with the MAGE-A3 immunotherapeutic was well-tolerated and immunogenic, inducing large 
increases in anti-MAGE-3 antibody levels, but without translation into clinical efficacy. The 
MAGRIT study, a similarly designed Phase 3 trial of adjuvant MAGE-A3 immunotherapeutic 
in patients with resected NSCLC that became available before study end, drew similar 
conclusions.23 Despite initially encouraging, but ultimately discordant, results from Phase 2 
studies, treatment with the MAGE-A3 immunotherapeutic did not improve DFS, OS or any 
other clinical outcome measure in the overall population, nor in subgroups according to 
tumour characteristics or treatment procedures. Although a gene signature potentially 
predictive of clinical benefit from MAGE-A3 immunotherapeutic over placebo in the GS+ 
population was identified in the training set, it could not be clinically validated in the test set. 
Of note, a Th1/IFNƴ  8-gene prognostic gene signature associated with outcome in the 
placebo arm of the training set was validated in the test set of this study.22 Even though the 
validation of the predictive gene signature using the adaptive signature design did not 
 
 
This is the last approved revised version prior to journal acceptance. This version differs from the final 
version following Editorial change prior to publication. 
23 
succeed, we have shown it is feasible to use this approach for optimisation and validation of 
biomarkers for which not all parameters have been set at the start of the clinical trial.  
We do not believe the study had any major limitations in design or analysis. A total of 1345 
patients were randomised and started treatment and the required number of events (850) 
was reached at the time of the final analysis of the first co-primary objective. The study 
groups were well balanced and unsuspected bias or confounding factors that might have 
influenced the outcome are unlikely. The percentage of patients who received previous 
treatment with interferon and/or anti-CTLA4 was similar in both treatment groups. 
Of note, the study did not have a pre-specified stopping criteria (futility analysis). This was 
because safety was overseen by an IDMC that reviewed study data on a 6-monthly basis 
throughout the study conduct and did not identify any safety concerns; no recognised 
alternative treatment option was available in absence of recurrence; and the implementation 
of a futility rule was not compatible with the search for a subgroup of subjects with a 
potentially more pronounced benefit from treatment (GS+), for which the assessment 
occurred later in the course of the study. 
The reasons underlying the lack of clinical efficacy in our study are speculative, but could be 
related to the choice of antigen or immunostimulant, and/or the absence of the induction of 
T-cell responses, particularly CD8+ responses. We may have selected a target population 
with disease too advanced for successful vaccine immunotherapy treatment. Of note, the 
observed median DFS of approximately 11 months is shorter than the reference 13-month 
median DFS in a similar population reported by Eggermont et al.3 Although reflecting real-
world practice, there were a high percentage of subjects with unknown primaries (TxN1b-
N2b-N3 M0) in the study. Although some reports suggest differences in outcome in patients 
with unknown primary melonoma,24 we observed no treatment effect in this subgroup in the 
exploratory subgroup analyses.  
MAGE-A3 was initially an attractive immunotherapeutic candidate because it is one of the 
most immunogenic cancer testis antigens and is human leukocyte antigen (HLA)-
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independent.8 The lack of efficacy in this trial could have been due to failure in one or 
multiple steps of the cancer immunity cycle,25 including, failure to mount an appropriate anti-
tumour immune response and mechanisms of immune evasion and suppression. The 
success of adoptively transferred and genetically modified T-cells in treating haematological 
malignancies and solid tumours, confirms the pivotal role of cytotoxic reactive T-cells in anti-
tumour response.26 We observed low or absent CD8+ responses in the Phase 2 study of the 
MAGE-A3 immunotherapeutic,10 which seems likely to have contributed to the lack of clinical 
effect. Immunotherapeutics aim to induce anti-tumour T-cell responses but its effects can be 
inhibited by many immunosuppressive mechanisms.  These include the loss of major 
histocompatibility complex class I, expression of ligands for inhibitory receptors 
(programmed death-ligand 1, CD200, HLA‑E), infiltration with suppressive cells, secretion of 
indoleamine 2,3‑dioxygenase, and secretion of immune-suppressive cytokines. Thus, 
immunotherapeutics might be more successful when used in early diseases stages when 
immune suppression might be less pronounced, and when combined with other treatments 
that can activate anti-tumour T-cell responses.27  In the future, the most promising 
combination may be an immunotherapeutic with check point inhibitor for maintaining the 
activation of cytotoxic T cells against melanoma antigens, with the advantage of the 
excellent tolerance of vaccines.  
The treatment of metastatic melanoma has changed dramatically in the past 5 years with the 
availability of BRAF/MEK inhibitors as well as multiple checkpoint inhibitors, which are 
immunopotentiators that are not specifically analogous to the MAGE-A3 immunotherapeutic. 
These drugs have changed the field of adjuvant therapy in melanoma. In the BRIM-8 trial, 
adjuvant vemurafenib provided substantial benefit to patients with completely resected stage 
IIC-IIIB BRAFV600-positive melanoma at high recurrence risk, where fewer DFS events and 
DMFS events were observed with vemurafenib compared to placebo. However, the benefit 
of this same agent was not significant in patients with resected stage IIIC melanoma, where 
a trend towards improved DFS was seen. The OS data are still immature for both cohorts. 
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The benefit of IFN in metastatic disease is well documented to be in the order of a 15% 
objective response, and the benefit of IFN in the adjuvant therapy of melanoma has been 
approximately 25-33% relapse frequency reduction (HR 0.28-0.33) in trials E1684-E1694. 
Ipilimumab prolongs both DFS  and OS in Stage III melanoma but causes severe adverse 
events;28 PD-1 inhibitors in the adjuvant setting have very recently shown significant benefit 
in DFS over ipilimumab although OS benefits are not yet mature.5 Trials designed to 
increase the efficacy of checkpoint inhibitors in multiple combinations are ongoing. As yet, it 
is unknown if combinations of antigen specific immunotherapies and checkpoint inhibitors 
might also improve efficacy; although the combination of gp100 and the first-generation 
CTLA4 checkpoint inhibitor ipilimumab, provided no additional benefits in patients with 
advanced melanoma.29 
Research in context 
Evidence before this study 
We conducted a PubMed search on 26 November 2017 using the terms “melanoma AND 
(vaccine OR immunotherapeutic) AND clinical trials, phase 3” without limitations on date or 
language. We identified eight relevant studies in patients with resected melanoma (Stages I-
IV) who had received different types of immunotherapies/vaccines. None of the studies 
reported that treatment improved clinical outcome in the adjuvant setting.  
Added value of this study 
Based on the available biological and clinical information from the Phase 2 studies, it was 
considered that a Phase 3 study using the MAGE-A3 immunotherapeutic in patients with 
Stage 3b melanoma was warranted. Both MAGRIT and DERMA provide conclusive 
evidence of the acceptable clinical safety profile of the MAGE-A3 immunotherapeutic, but 
treatment did not provide clinical benefit in either patient population. The clinical 
development of the MAGE-A3 immunotherapeutic for these indications has therefore been 
stopped. Nevertheless, an acceptable safety profile of the MAGE-A3 immunotherapeutic has 
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been demonstrated in large populations of patients with melanoma or NSCLC, supporting 
the feasibility of the approach in terms of tolerability.  
DERMA confirms a high rate of early disease recurrence among patients with resected 
Stage III melanoma. With 1345 patients studied, the study provides a large body of 
information on disease progression and clinical outcomes in the adjuvant setting of 
melanoma, and provides insights into the clinical characteristics and outcomes in patients 
receiving contemporary surgery for melanoma treatment. An adaptive signature design was 
used to optimise and validate a potentially predictive gene signature in this study using a 
split-sample approach. A previously reported Th1/IFNƴ gene signature was not predictive of 
a treatment benefit from the MAGE-A3 immunotherapeutic over placebo in the GS+ 
population, in this setting but found to be strongly associated to clinical outcome in the 
placebo arm (prognostic). A novel potentially predictive gene signature found in the training 
set in this study failed to be validated in the test set. The feasibility of using the adaptive 
signature design for biomarker validation in a registration study has been demonstrated 
here. 
Implications of all the available evidence 
We and others have now shown that antigen specific immunotherapeutics alone is not 
efficacious in this clinical setting. The failure of these approaches might be due to inability to 
mount appropriate anti-tumour immune responses, and/or the need to overcome tumour 
immune suppressive mechanisms as shown with checkpoint inhibitors. Although considered 
as an immunogenic antigen, T cell repertoire specific for the characterized class I epitopes 
are of rather low frequencies in melanoma patients. Targeting other shared tumor antigens, 
together with MAGE-A3 antigen could favor the amplification of immune responses in treated 
patients. Ideal target antigens for vaccination purposes should combine different properties 
such as tumor-specific expression, and the presence of vast and high avidity specific T cell 
repertoire. 
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Table 1: Demographic and disease characteristics (Total Treated population– as 
randomised)*  
Characteristics  MAGE-A3  
N=893 
Placebo  
N=452 
Age at screening (years) Mean (SD) 56·1 (13·5) 56·1 (13·6) 
 Range  18-87 20-88 
 Median (IQR) 57 (44-66) 57 (44-66) 
Sex n (%) Women  344 (38·5) 189 (41·8) 
 Men 549 (61·5) 263 (58·2) 
Primary tumour ulceration Yes 322 (36·1) 157 (34·7) 
 No 397 (44·5) 210 (46·5) 
 Unknown/Missing  174 (19·5) 85 (18·8) 
Tumour stage T1 122 (13·7) 65 (14·4) 
 T2 197 (22·1) 100 (22·1) 
 T3 202 (22·6) 110 (24·3) 
 T4 210 (23·5) 101 (22·3) 
 TX 162 (18·1) 76 (16·8) 
Nodal stage  N1 a 1 (0·1) 0 (0·0) 
 N1 b 356 (39·9) 181 (40·0) 
 N2 a 1 (0·1) 2 (0·4) 
 N2 b 272 (30·5) 137 (30·3) 
 N3 263 (29·5) 132 (29·2) 
Performance status n(%) 0 740 (82·9) 378 (83·6) 
 1 153 (17·1) 73 (16·2) 
 3 0 1 (0·2) 
Stage n (%) Stage IIIA 1 (0·1) 0  
 Stage IIIB 292 (32·7) 155 (34·3) 
 Stage IIIC 483 (54·1) 241 (53·3) 
 Undefined Stage III (TX) 109 (12·2)  53 (11·7) 
 Stage IV 8 (0·9) 3 (0·7) 
Prior therapy Interferon 130 (14·6) 67 (14·8) 
 Anti-CTL-A4 3 (0·3) 2 (0·4) 
 Interferon and/or anti-CTL-A4 133 (14·9) 69 (15·3) 
 Radiotherapy 8 (0·9) 5 (1·1) 
Number of lymph nodes invaded 1 360 (40·3) 187 (41·4) 
 2 198 (22·2) 89 (19·7) 
 3 81 (9·1) 51 (11·3) 
 3+ 223 (25·0) 110 (24·3) 
 Matted 31 (3·5) 15 (3·3) 
Extracapsular extension No 591 (66·2) 304 (67·3) 
 Yes 300 (33·6) 148 (32·7) 
 Missing  2 (0·2) 0  
Region Europe 658 (73·7) 327 (72·3) 
 International 98 (11·0) 50 (11·1) 
 North America 137 (15·3) 75 (16·6) 
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N = total number of patients, n (%) = number/percentage of patients with the defined characteristic, SD = standard deviation; 
IQR = inter quartile range. 
* The final analysis was performed on the population as-randomized: one patient who was randomised to the treatment 
group received placebo and three patients who were randomised to placebo received MAGE-A3 immunotherapeutic. This 
led to differences in the denominator in populations evaluated for efficacy (as-randomised) and safety (as treated).  
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Table 2: Summary of adverse events within 31 days of administration, by maximum Common Terminology Criteria for Adverse Events 
grade (Total Treated population, follow-up analysis – as treated)  
 MAGE-A3 
 N = 894 
PLACEBO 
 N = 450 
 Grade Grade 
 1/2 3 4 5 Unknown 1/2 3 4 5 Unknown 
Preferred term ( 10% of patients)  n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) 
Any event 696 (78%) 97 (11%) 28 (3%) 1 (<1%) 0 278 (62%) 46 (10%) 9 (2%) 1 (<1%) 0 
Pyrexia 376 (42%) 5 (<1%) 0 0 0 35 (8%) 0 0 0 0 
Injection site pain 324 (36%) 1 (<1%) 0 0 0 22 (5%) 0 0 0 0 
Influenza like illness 261 (29%) 0 0 0 0 30 (7%) 0 0 0 0 
Fatigue 202 (23%) 8 (<1%) 0 0 0 62 (14%) 1 (<1%) 0 0 0 
Headache 200 (22%) 5 (<1%) 0 0 0 53 (12%) 2 (<1%) 0 0 0 
Myalgia 185 (21%) 3 (<1%) 0 0 0 23 (5%) 0 0 0 0 
Pain 186 (21%) 5 (<1%) 0 0 0 19 (4%) 0 0 0 0 
Asthenia 140 (16%) 9 (1%) 0 0 0 43 (10%) 3 (<1%) 0 0 0 
Chills 177 (20%) 2 (<1%) 0 0 0 15 (3%) 0 0 0 0 
Injection site reaction 160 (18%) 0 0 0 0 6 (1%) 0 0 0 0 
Nausea 123 (14%) 0 0 0 0 32 (7%) 0 0 0 0 
Erythema 137 (15%) 0 0 0 1 (<1%) 10 (2%) 0 0 0 0 
Pain in extremity 113 (13%) 2 (<1%) 0 0 0 25 (6%) 1 (<1%) 0 0 0 
Injection site erythema 90 (10%) 0 0 0 0 3 (<1%) 0 0 0 0 
Primary system organ class   
Any event 696 (78%) 97 (11%) 28 (3%) 1 (<1%) 0 278 (62%) 46 (10%) 9 (2%) 1 (<1%) 0 
General disorders and administration site 
conditions 
735 (82%) 25 (3%) 0 0 1 (<1%) 189 (42%) 4 (<1%) 0 0 0 
Musculoskeletal and connective tissue 
disorders 
365 (41%) 17 (2%) 1 (<1%) 0 0 103 (23%) 8 (2%) 0 0 0 
Nervous system disorders 287 (32%) 11 (1%) 1 (<1%) 0 0 83 (18%) 6 (1%) 0 0 0 
Skin and subcutaneous tissue disorders 280 (31%) 1 (<1%) 0 0 0 84 (19%) 0 0 0 0 
Gastrointestinal disorders 235 (26%) 4 (<1%) 1 (<1%) 0 0 79 (18%) 2 (<1%) 0 0 0 
Infections and infestations 180 (20%) 14 (2%) 3 (<1%) 0 0 91 (20%) 6 (1%) 1 (<1%) 0 0 
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Respiratory, thoracic and mediastinal disorders 84 (9%) 2 (<1%) 2 (<1%) 0 0 40 (9%) 0 0 0 0 
Vascular disorders 69 (8%) 11 (1%) 1 (<1%) 0 0 35 (8%) 9 (2%) 0 0 0 
Psychiatric disorders 77 (9%) 0 1 (<1%) 0 1 (<1%) 31 (7%) 0 1 (<1%) 0 0 
Neoplasms benign, malignant and unspecified 
(including cysts and polyps) 
32 (4%) 16 (2%) 17 (2%) 0 0 23 (5%) 10 (2%) 7 (2%) 0 0 
Investigations 62 (7%) 5 (<1%) 0 0 0 26 (6%) 1 (<1%) 0 0 0 
Injury, poisoning and procedural complications 56 (6%) 4 (<1%) 0 0 0 29 (6%) 1 (<1%) 0 0 0 
Metabolism and nutrition disorders 57 (6%) 3 (<1%) 0 0 0 13 (3%) 0 0 0 0 
Blood and lymphatic system disorders 24 (3%) 4 (<1%) 0 0 0 17 (4%) 0 0 1 (<1%) 0 
Reproductive system and breast disorders 27 (3%) 0 0 0 0 12 (3%) 1 (<1%) 0 0 0 
Eye disorders 21 (2%) 0 0 0 0 13 (3%) 3 (<1%) 0 0 0 
Ear and labyrinth disorders 19 (2%) 0 0 0 0 17 (4%) 0 0 0 0 
Cardiac disorders 12 (1%) 5 (<1%) 1 (<1%) 1 (<1%) 0 4 (<1%) 0 0 0 0 
Renal and urinary disorders 14 (2%) 4 (<1%) 0 0 0 4 (<1%) 1 (<1%) 0 0 0 
Hepatobiliary disorders 5 (<1%) 1 (<1%) 0 0 0 4 (<1%) 1 (<1%) 0 0 0 
Immune system disorders 4 (<1%) 0 0 0 0 7 (2%) 0 0 0 0 
Endocrine disorders 4 (<1%) 0 0 0 0 2 (<1%) 0 0 0 0 
N = number of patients with at least one administered dose 
n/% = number/percentage of patients reporting the adverse event. 
MedDRa = Medical Dictionary for Regulatory Activities 
Unknown = Grade not known 
Preferred terms for adverse events reported by at least 10% of patients in any group. Primary system organ class summarises all adverse events.  
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Table 4: Potential immune-mediated diseases determined from a predefined list of 
Preferred Terms and/or by the investigator (Total Treated population, follow-up analysis)  
 
MedDRA System Organ Class MedDRA Preferred Term 
MAGE-A3 
 N = 894 
Placebo 
 N = 450 
  n (%) n (%) 
Any event Any event 33 (4%) 23 (5%) 
Blood and lymphatic system disorders Thrombocytopenic purpura 0 1  
Endocrine disorders Autoimmune thyroiditis 3  0 
 Basedow’s disease 1  1  
 Hypothyroidism 1  0 
 Lymphocytic hypophysitis 0 1  
 Polyglandular autoimmune syndrome type II 0 1  
Eye disorders Vision blurred 1  0 
Gastrointestinal disorders Colitis ulcerative 0 1  
Hepatobiliary disorders Autoimmune hepatitis 1  1  
Immune system disorders Sarcoidosis 0 2  
Musculoskeletal and connective tissue 
disorders 
Polymyalgia rheumatica 0 1  
Neoplasms benign, malignant and unspecified 
(including cysts and polyps) 
Langerhans’ cell histiocytosis 0 1  
Nervous system disorders Multiple sclerosis 1  0 
 VIIth nerve paralysis 1  1  
Respiratory, thoracic and mediastinal disorders Pulmonary fibrosis 1  1  
Skin and subcutaneous tissue disorders Alopecia areata 1  0 
 Psoriasis 1  1  
 Skin hypopigmentation 1  0 
 Vitiligo 20 (2%) 13 (3%) 
N = total number of patients, n (%) = number/percentage of patients 
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Figure 1  
Subject flow at the follow-up analysis (18 August 2015) – as treated  
Footnotes: 
N, n = Number of participants 
1 Invalid = gDNA contamination or result out of range. Quantity not sufficient = not 
enough tumour tissue or insufficient RNA. Other = improper specimen. Missing = 
informed consent signed but no sample received.  
2 Main reasons for not meeting eligibility criteria: Patient did not sign study informed 
consent (n=197), ineligible disease stage (106), residual disease post-surgery (280), 
patients unable to comply with study requirements (63), In-transit metastases (62). Note 
that patients could be ineligible for more than one reason. 
3 The main reason for not starting treatment was ineligibility  
4 Treatment completion = 13 doses administered and concluding visit attended. 
The final analysis was performed on the population as-randomized: one patient who was 
randomised to the treatment group received placebo and three patients who were 
randomised to placebo received MAGE-A3 immunotherapeutic. This led to differences in 
the denominator in populations evaluated for efficacy (as-randomised) and safety (as 
treated). 
Between the final analysis done on the overall population (May 2013) and the follow-up 
analysis in the GS+ population (August 2015), one patient was found to have an invalid 
study informed consent (consent form for screening signed twice in error instead of the 
consent form for study participation). This patient’s data were included in the final 
analysis and in the building of the gene signature classifier (this patient was part of the 
training set), but were not included in the follow-up analysis.   
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Figure 2 Disease-free survival (DFS) and Overall survival (OS) in Total treated population 
and in the GS+ population (follow-up analysis, as randomised).  
 
Figure 3 Forest plots for Disease-free survival in subgroups defined by baseline and 
treatment variables 
HR (Hazard ratio) and 95% CI (confidence intervals) from a Cox regression model by 
subgroup, using Efron method to handle ties 
LL, UL = 95% Lower and Upper confidence limits 
P-value = Likelihood ratio test for interaction with treatment 
Patients with missing values for at least one baseline variable are discarded 
N category = nodal stage 
T category = tumour stage 
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Figure 1 
 
 
  
Treatment withdrawal:
Recurrence (537); consent 
withdrawal (18); non-serious 
adverse event (4); serious 
adverse event (10); protocol 
violation (5); other (10)
Treatment withdrawal:
Recurrence (268); consent 
withdrawal (9); non-serious 
adverse event (0); serious 
adverse event (5); protocol 
violation (3); other (7)
Total number screened N= 3914
Study discontinuation:
Consent withdrawal (not due to an 
adverse event) (46); death (399), 
lost-to-follow-up (27), other (6)
Study discontinuation:
Consent withdrawal (not due to an 
adverse event) (23); death (198); 
lost-to-follow-up (20), other (1)
MAGE-A3 expression results1:
Invalid: n=155 (4.0%)
Missing: n=220 (5.6%)
Quantity not sufficient n=323 (8.3%)
Other n=34 (0.9%)
Total missing: n=732/3914 (18.7%)
Results achieved in N=3182 (81.3%) 
MAGE-A3+ : n=2092 (66%)
MAGE-A3 - : n=1090 (34%)
710 MAGE-A3-positive not 
included: 671 (94.5%) did not meet 
all eligibility criteria2
Total randomised N= 1390
Patients who did not start treatment3:
MAGE-A3 group n=28
Placebo group n=18
Total treated population N = 1344
(cohort for all efficacy endpoints)
Treatment completion4 n=310 Treatment completion4 n=158
Study completion: n=209 (23%) Study completion n=107 (24%)
MAGE-A3
Total treated cohort N=894
Placebo
Total treated cohort N=450
Total number with recurrence: 889  
Total number of deaths: 610
Patients who were ineligible due to stage 
but included in the analysis:
MAGE-A3 group n=11
Placebo group n=9
9 patients (MAGE-A3-
negative/unknown/inconclusive 
results) were randomised by 
error but never started treatment.
One patient with invalid ICF was 
removed from all analyses after 
2013
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Figure 2 
Total population GS+ population 
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Figure 3 
 
 
 
 
